A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo

Human Gene Therapy

Volumn 15, Issue 5, 2004, Pages 433-443

  Ogawara, Ken Ichi ^a   Rots, Marianne G ^a   Kok, Robbert J ^a   Moorlag, Henk E ^a   Van Loenen, Anne Miek ^a   Meijer, Dirk K F ^a   Haisma, Hidde J ^a   Molema, Grietje ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; CD51 ANTIGEN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FUNCTIONAL GROUP; GREEN FLUORESCENT PROTEIN; LUCIFERASE; MACROGOL; RECOMBINANT ENZYME;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CELL ACTIVATION; CIRCULATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; ENDOTHELIUM CELL; GENE TARGETING; GENE TRANSFER; HUMAN; HUMAN CELL; MALE; MOLECULE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REPORTER GENE; SKIN INFLAMMATION; TRANSGENE; VASCULAR ENDOTHELIUM; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; AREA UNDER CURVE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC ENGINEERING; GENETIC VECTORS; HELA CELLS; HUMANS; LUCIFERASES; MALE; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECEPTORS, VIRUS; TRANSGENES; TROPISM; UMBILICAL VEINS;

ADENOVIRIDAE; ANIMALIA; COXSACKIEVIRUS; DNA VIRUSES;

EID: 2442624634     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340460745766     Document Type: Article

References (34)

1. ALAMANY, R., and CURIEL, D.T. (2001). CAR-binding ablation does not change biodistribution and toxicity of adenovirus vectors. Gene Ther. 8, 1347-1353.
2. ASGEIRSDOTTIR, S.A., KOK, R.J., EVERTS, M., MEIJER, D.K.F., and MOLEMA, G. (2003). Delivery of pharmacologically active dexamethasone into activated endothelial cells by dexamethasone-anti-E-selectin immunoconjugate. Biochem. Pharmacol. 65, 1729-1739.
3. BERGELSON, J.M., CUNNINGHAM, J.A., DROGUETT, G., KURT-JONES, E.A., KRITHIVAS, A., HONG, J.S., HORWITZ, M.S., CROWELL, R.L., and FINBERG, R.W. (1997). Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
4. BERNAL, R.M., SHARMA, S., GARDNER, B.K., DOUGLAS, J.T., BERGELSON, J.M., DUBINETT, S.M., and BATRA, R.K. (2002). Soluble coxsackievirus adenovirus receptor is a putative inhibitor of adenoviral gene transfer in the tumor milieu. Clin. Cancer Res. 8, 1915-1923.
5. BOURI, K., FEERO, W.G., MYERBURG, M.M., WICKHAM, T.J., KOVESDI, I., HOFFMAN, E.P., and CLEMENS, P.R. (1999). Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. Hum. Gene Ther. 10, 1633-1640.
6. BROOKS, P.C., CLARK, R.A., and CHERESH, D.A. (1994). Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264, 569-571.
7. CARMELIET, P., and JAIN, R.K. (2000). Angiogenesis in cancer and other diseases. Nature 14, 249-257.
8. CARSON, S.D., HOBBS, J.T., TRACY, S.M., and CHAPMAN, N.M. (1999). Expression of the coxsackievirus and adenovirus receptor in cultured human umbilical vein endothelial cells. J. Virol. 73, 7077-7079.
9. COOKE, S.P., BOXER, G.M., LAWRENCE, L., PEDLEY, R.B., SPENCER, D.I., BEGENT, R.H., and CHESTER, K.A. (2001). A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. Cancer Res. 61, 3653-3659.
10. CROYLE, M.A., CHIRMULE, N., ZHANG, Y., and WILSON, J.M. (2001). "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 75, 4792-4801.
11. EBNET, K., and VESTWEBER, D. (1999). Molecular mechanisms that control leukocyte extravasation: The selectins and the chemokines. Histochem. Cell Biol. 112, 1-23.
12. ELLERBY, H.M., ARAP, W., ELLEBY, L.M., KAIN, R., ANDRUSIAK, R., RIO, G.D., KRAJEWSKI, S., LOMBARDO, C.R., RAO, R., RUOSLAHTI, E., BREDESEN, D.E., and PASQUALINI, R. (1999). Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5, 1032-1038.
13. EVERTS, M., KOK, R.J., ASGEIRSDOTTIR, S.A., MELGERT, B.N., MOOLENAAR, T.J., KONING, G.A., VAN LUYN, M.J., MEIJER, D.K.F., and MOLEMA, G. (2002). Selective intracellular delivery of dexamethasone into activated endothelial cells using an E-selectin-directed immunoconjugate. J. Immunol. 168, 883-889.
14. EVERTS, M., KONING, G.A., KOK, R.J., ASGEIRSDOTTIR, S.A., VESTWEBER, D., STORM, G., MEIJER, D.K.F., and MOLEMA, G. (2003). In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium. Pharm. Res. 20, 64-72.
15. HIDAKA, C., MILANO, E., LEOPOLD, P.L., BERGELSON, J.M., HACKETT, N.R., FINBERG, R.W., WICKHAM, T.J., KOVESDI, I.P., and CRYSTAL, R.G. (1999). CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J. Clin. Invest. 103, 579-587.
16. HUARD, J., LOCHMULLER, H., ACSADI, G., JANI, A., MASSIE, B., and KARPATI, G. (1995). The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 2, 107-115.
17. IIMURO, Y., NISHIURA, T., HELLERBRAND, C., BEHRNS, K.E., SCHOONHOVEN, R., GRISHAM, J.W., and BRENNER, D.A. (1998). NFκB prevents apoptosis and liver dysfunction during liver regeneration. J. Clin. Invest. 101, 802-811.
18. KOK, R.J., SCHRAA, A.S., BOS, E.J., MOORLAG, H.E., ASGEIRSDOTTIR S.A., EVERTS, M., MEIJER, D.K.F., and MOLEMA, G. (2002). Preparation and functional evaluation of RGD-modified proteins as avB3 integrin directed therapeutics. Bioconjugate Chem. 13, 128-135.
19. KONING, G.A., MORSELT, H.W.M., VELINOVA, M.J., DONGA, J., GORTER, A., ALLEN, T.M., ZALIPSKY, S., KAMPS, J.A.A.M., and SCHERPHOF, G.L. (1999). Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine (FUdR) from immunoliposomes to colon cancer cells. Biochim. Biophys. Acta 1420, 153-167.
20. KRASNYKH, V.N., MIKHEEVA, G.V., DOUGLAS, J.T., and CURIEL, D.T. (1996). Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virol. 70, 6839-6846.
21. KUSHIDA, T., LIVOLTI, G., GOODMAN, A.I., and ABRAHAM, N.G. (2002). TNF-α-mediated cell death is attenuated by retrovirus delivery of human heme oxygenase-1 gene into human microvessel endothelial cells. Transplant. Proc. 34, 2973-2978.
22. LUO, J., PARANYA, G., and BISCHOFF, J. (1999). Noninflammatory expression of E-selectin is regulated by cell growth. Blood 93, 3785-3791.
23. MODLICH, U., PUGH, C.W., and BICKNELL, R. (2000). Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther. 7, 896-902.
24. PALEOLOG, E.M. (2002). Angiogenesis in rheumatoid arthritis. Arthritis Res. 4, S81-S90.
25. PASQUALINI, R., KOIVUNEN, E., and RUOSLAHTI, E. (1997). Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15, 542-546.
26. PFAFF. M., TANGEMANN, K., MULLER, B., GURRATH, M., MULLER, G., KESSLER, H., TIMPL, R., and ENGEL, J. (1994). Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J. Biol. Chem. 269, 20233-20238.
27. REYNOLDS, P., DMITRIEV, I., and CURIEL, D. (1999). Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther. 6, 1336-1339.
28. REYNOLDS, P.N., NICKLIN, S.A., KALIBEROVA. L., BOATMAN. B.C., GRIZZLE, W.E., BALYASNIKOVA, I.V., BAKER, A.H., DANILOV, S.M., and CURIEL, D.T. (2001). Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat. Biotechnol. 19, 838-842.
29. ROMANCZUK, H., GALER, C.E., ZABNER, J., BARSOMIAN, G., WADSWORTH, S.C., and O'RIORDAN, C.R. (1999). Modification of an adenoviral vector with biologically selected peptides: A novel strategy for gene delivery to cells of choice. Hum. Gene Ther. 10, 2615-2626.
30. SCHRAA, A.J., KOK, R.J., MOORLAG, H.E., BOS, E.J., PROOST, J.H., MEIJER, D.K.F., DE LEIJ, L.F., and MOLEMA, G. (2002). Targeting of RGD-modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study. Int. J. Cancer 102, 469-475.
31. SULLIVAN, D.E., DASH, S., DU, H., HIRAMATSU, N., AYDIN, F., KOLLS, J., BLANCHARD, J., BASKIN, G., and GERBER, M.A. (1997). Liver-directed gene transfer in non-human primates. Hum. Gene Ther. 8, 1195-1206.
32. VEIKKOLA, T., KARKKAINEN, M., CLAESSON-WALSH, L., and ALITALO, K. (2000). Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60, 203-212.
33. WICKHAM, T.J., ROELVINK, P.W., BROUGH, D.E., and KOVESDI, I. (1996). Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat. Biotechnol. 14, 1570-1573.
34. WICKHAM, T.J., TZENG, E., SHEARS, L.L. 2nd, ROELVINK, P.W., LI, Y., LEE, G.M., BROUGH, D.E., LIZONOVA, A., and KOVESDI, I. (1997). Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71, 8221-8229.